Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 1.83 USD 4.57% Market Closed
Market Cap: 611.1m USD

Wall Street
Price Targets

IOVA Price Targets Summary
Iovance Biotherapeutics Inc

Wall Street analysts forecast IOVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IOVA is 19.57 USD with a low forecast of 5.05 USD and a high forecast of 33.6 USD.

Lowest
Price Target
5.05 USD
176% Upside
Average
Price Target
19.57 USD
969% Upside
Highest
Price Target
33.6 USD
1 736% Upside
Iovance Biotherapeutics Inc Competitors:
Price Targets
ALGEN
Genoway SA
87% Upside
VIR
Vir Biotechnology Inc
560% Upside
688235
Beigene Ltd
15% Upside
300896
Imeik Technology Development Co Ltd
32% Upside
STTK
Shattuck Labs Inc
132% Upside
IKT
Inhibikase Therapeutics Inc
292% Upside
2696
Shanghai Henlius Biotech Inc
20% Downside
2171
CARsgen Therapeutics Holdings Ltd
54% Downside

Revenue
Forecast

Revenue Estimate
Iovance Biotherapeutics Inc

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 3 years is 68%.

N/A
Past Growth
68%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-65%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IOVA's stock price target?
Price Target
19.57 USD

According to Wall Street analysts, the average 1-year price target for IOVA is 19.57 USD with a low forecast of 5.05 USD and a high forecast of 33.6 USD.

What is Iovance Biotherapeutics Inc's Revenue forecast?
Projected CAGR
68%

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 3 years is 68%.

Back to Top